Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Gemfibrozil
Drug ID BADD_D01012
Description Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]
Indications and Usage Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.[L8525] Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.[L8525]
Marketing Status approved
ATC Code C10AB04
DrugBank ID DB01241
KEGG ID D00334
MeSH ID D015248
PubChem ID 3463
TTD Drug ID D05VIX
NDC Product Code 15440-1025; 51655-143; 57237-163; 65862-624; 71205-169; 71335-0899; 75834-131; 62991-2883; 65862-424; 50090-5808; 53002-2068; 55700-493; 68071-4053; 71610-601; 0615-8354; 43063-921; 50268-350; 68788-7964; 70934-255; 71335-0971; 61919-967; 68071-2296; 71610-107; 65691-0089; 24658-260; 43602-452; 71335-0051; 16714-101; 70518-1563; 71335-2025; 49452-3263; 16571-784; 63187-146; 63187-772; 70771-1431; 71335-0515; 76282-225; 0071-0737; 60687-224; 68382-553; 71209-008; 71335-1902; 72578-066; 71335-1996; 71610-200; 66651-905; 31722-128; 42806-260; 69097-821; 72865-186; 43063-745; 53002-1068
UNII Q8X02027X3
Synonyms Gemfibrozil | Gemfibrosil | Ausgem | Bolutol | Chem mart Gemfibrozil | CI-719 | CI 719 | CI719 | DBL Gemfibrozil | Decrelip | Gemfi 1A Pharma | Gemfibrozilo Bayvit | Bayvit, Gemfibrozilo | Gemfibrozilo Bexal | Gemfibrozilo Ur | Gemhexal | Gen-Gemfibrozil | Gen Gemfibrozil | GenGemfibrozil | GenRX Gemfibrozil | Gemfibrozil, GenRX | Healthsense Gemfibrozil | Gemfibrozil, Healthsense | Jezil | Lipazil | Lipox Gemfi | Litarek | Lopid | Lipur | Lopid R | Novo-Gemfibrozil | Novo Gemfibrozil | Nu-Gemfibrozil | Nu Gemfibrozil | NuGemfibrozil | Pilder | PMS-Gemfibrozil | PMS Gemfibrozil | SBPA Gemfibrozil | Gemfibrozil, SBPA | Terry White Chemists Gemfibrozil | Trialmin | Apo-Gemfibrozil | Apo Gemfibrozil | ApoGemfibrozil
Chemical Information
Molecular Formula C15H22O3
CAS Registry Number 25812-30-0
SMILES CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Drug hypersensitivity10.01.01.0010.012460%Not Available
Drug interaction08.06.03.0010.000880%Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.0010.000236%
Dysphagia07.01.06.0030.000365%
Eczema23.03.04.006--
Eosinophilia01.02.04.001--
Extrasystoles02.03.02.003--Not Available
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.0020.000633%
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Gout15.01.06.001; 14.09.01.001--Not Available
Headache17.14.01.001--
Hepatic steatosis14.08.04.005; 09.01.07.0030.000107%Not Available
Hepatitis cholestatic09.01.01.0020.000397%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.000107%Not Available
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hypersensitivity10.01.03.0030.000419%
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Infertility male21.03.02.002--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Linear IgA disease10.04.02.006; 23.03.01.0150.000161%Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages